The effect of methylation on the let-7-BCL2L1-BCL2 axis and the potential use of hypomethylating and BH3 mimetic drugs in histiocytic neoplasms

Leukemia. 2024 Nov 8. doi: 10.1038/s41375-024-02459-5. Online ahead of print.

Mali Salmon-Divon^#^{1

2}, Refael Meyuchas^#^{1

3}, Ofer Shpilberg^{2

3

4}, Elimelech Okon⁵, Jamal Benhamida⁶, Mariko Yabe⁶, Kseniya Petrova-Drus⁶, Tal Zvida-Bloch^{1

3}, May Basood⁴, Roei Mazor⁴, Benjamin H Durham⁷, Julien Haroche⁸, Omar Abdel-Wahab⁷, Eli L Diamond^#⁹, Oshrat Hershkovitz-Rokah^#^{10

11}

¹ Department of Molecular Biology, Faculty of Natural Sciences, Ariel University, Ariel, Israel.
² Adelson School of Medicine, Ariel University, Ariel, Israel.
³ Translational Research Lab, Assuta Medical Centers, Tel-Aviv, Israel.
⁴ Clinic of Histiocytic Neoplasms, Institute of Hematology, Assuta Medical Center, Tel-Aviv, Israel.
⁵ Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
⁶ Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁷ Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁸ Service de Médecine Interne, Hôpital Universitaire Pitié Salpêtrière-Charles Foix, Sorbonne Université, Faculté de Médecine, Paris, France.
⁹ Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. [email protected].
¹⁰ Department of Molecular Biology, Faculty of Natural Sciences, Ariel University, Ariel, Israel. [email protected].
¹¹ Translational Research Lab, Assuta Medical Centers, Tel-Aviv, Israel. [email protected].

^# Contributed equally.

No abstract available

Grants and funding